These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 19663790)
1. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Shi Q; Shih CC; Lee KH Anticancer Agents Med Chem; 2009 Oct; 9(8):904-12. PubMed ID: 19663790 [TBL] [Abstract][Full Text] [Related]
2. ASC-J9 Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687 [TBL] [Abstract][Full Text] [Related]
3. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases. Hu H; Zhou H; Xu D Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796 [TBL] [Abstract][Full Text] [Related]
4. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation. Zhou DY; Ding N; Du ZY; Cui XX; Wang H; Wei XC; Conney AH; Zhang K; Zheng X Mol Med Rep; 2014 Sep; 10(3):1315-22. PubMed ID: 25060817 [TBL] [Abstract][Full Text] [Related]
5. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression. Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor (AR) degradation enhancer ASC-J9 Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251 [TBL] [Abstract][Full Text] [Related]
7. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Wen S; Chang HC; Tian J; Shang Z; Niu Y; Chang C Am J Pathol; 2015 Feb; 185(2):293-301. PubMed ID: 25432062 [TBL] [Abstract][Full Text] [Related]
8. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer. McCarty MF; Hejazi J; Rastmanesh R Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of curcumin derivatives targeting androgen receptor for castration-resistant prostate cancer therapy. Liu J; Ni Y; Zhou K; Wu G; Hu L; Zhu T; Xu D; Hu H Chem Biol Drug Des; 2024 Jul; 104(1):e14583. PubMed ID: 38991995 [TBL] [Abstract][Full Text] [Related]
10. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor. Guo H; Xu YM; Ye ZQ; Yu JH; Hu XY Pharmazie; 2013 Jun; 68(6):431-4. PubMed ID: 23875250 [TBL] [Abstract][Full Text] [Related]
11. Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Choi HY; Lim JE; Hong JH Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):343-9. PubMed ID: 20680030 [TBL] [Abstract][Full Text] [Related]
12. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin. Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804 [TBL] [Abstract][Full Text] [Related]
13. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044 [TBL] [Abstract][Full Text] [Related]
14. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. Lin L; Shi Q; Nyarko AK; Bastow KF; Wu CC; Su CY; Shih CC; Lee KH J Med Chem; 2006 Jun; 49(13):3963-72. PubMed ID: 16789753 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Dorai T; Gehani N; Katz A Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300 [TBL] [Abstract][Full Text] [Related]
16. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. Ohtsu H; Xiao Z; Ishida J; Nagai M; Wang HK; Itokawa H; Su CY; Shih C; Chiang T; Chang E; Lee Y; Tsai MY; Chang C; Lee KH J Med Chem; 2002 Nov; 45(23):5037-42. PubMed ID: 12408714 [TBL] [Abstract][Full Text] [Related]
18. Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential. Teymouri M; Barati N; Pirro M; Sahebkar A J Cell Physiol; 2018 Jan; 233(1):124-140. PubMed ID: 27996095 [TBL] [Abstract][Full Text] [Related]
19. Delivery of curcumin within emulsome nanoparticles enhances the anti-cancer activity in androgen-dependent prostate cancer cell. Bolat ZB; Islek Z; Sahin F; Ucisik MH Mol Biol Rep; 2023 Mar; 50(3):2531-2543. PubMed ID: 36607480 [TBL] [Abstract][Full Text] [Related]
20. Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts. Hong JH; Lee G; Choi HY Korean J Urol; 2015 Sep; 56(9):656-65. PubMed ID: 26366279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]